KR890001571A - 독소루비신 히드로클로라이드 수용액 - Google Patents

독소루비신 히드로클로라이드 수용액 Download PDF

Info

Publication number
KR890001571A
KR890001571A KR1019880008864A KR880008864A KR890001571A KR 890001571 A KR890001571 A KR 890001571A KR 1019880008864 A KR1019880008864 A KR 1019880008864A KR 880008864 A KR880008864 A KR 880008864A KR 890001571 A KR890001571 A KR 890001571A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
composition according
doxorubicin hydrochloride
citric acid
container
Prior art date
Application number
KR1019880008864A
Other languages
English (en)
Other versions
KR920004097B1 (ko
Inventor
아더 카플탄 머레이
케빈 페론 로버트
발라드 보가더스 죠셉
Original Assignee
원본미기재
브리스톨-마이어즈 컴페니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 브리스톨-마이어즈 컴페니 filed Critical 원본미기재
Publication of KR890001571A publication Critical patent/KR890001571A/ko
Application granted granted Critical
Publication of KR920004097B1 publication Critical patent/KR920004097B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

독소루비신 히드로클로라이드 수용액
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 독소루비신 히드로클로라이드 2-5mg/ml, 용액의 pH를 3-4로 조절하는데 필요한 양의 구연산 α-토코페롤, 나트륨 포름알데히드 비설파이트 및 3차-부틸히드로귀논 중에서 선택한 항산화제 0.1-2mg/ml 및 물을 함유하는 밀봉 용기중의 안정하고 멸균된 즉시 비 경구 투여용 용액의 약제 조성물.
  2. 제1항에 있어서, 탈기시킨 물이 사용되고 용기를 밀봉하기 전에 용액을 질소 정화시킨 약제 조성물.
  3. 제1항 또는 제2항에 있어서, 항산화제가 나트륨 포름알데히드 비설파이트인 약제 조성물.
  4. 제1항 또는 제2항에 있어서, 항산화제가 3차-부틸히드로귀논인 약제 조성물.
  5. 제1항 또는 제2항에 있어서, 항산화제가 α-토코페롤인 약제 조성물.
  6. 제1항에 있어서, 용기를 밀봉하기 전 질소정화시킨 용액 1ml당 독소루비신 히드로클로라이드 약 2mg, 구연산 약 0.2mg, 나트륨 포름알데히드 비설파이트 약 1mg 및 탈기시킨 물 충분량을 함유하는 약제 조성물.
  7. 제1항에 있어서, 용기를 밀봉시키기 전에 질소정화시킨 용액 1ml당 독소루비신 히드로클로라이드 약 2mg, 구연산 약02.mg, 나트륨 포름알데히드 비설파이트 약 1mg 및 탈기시킨 물 충분량을 함유하는 약제 조성물.
  8. 제1항에 있어서, 용기를 밀봉시키기 전에 질소정화시킨 용액 1ml당 독소루비신 히드로클로라이드 약 2mg, 구연산 약 0.2mg, α-토코페롤 약 1mg 및 탈기시킨 물 충분량을 함유하는 약제 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880008864A 1987-07-16 1988-07-15 독소루비신 히드로클로라이드 수용액 KR920004097B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7419087A 1987-07-16 1987-07-16
US074,190 1993-06-10

Publications (2)

Publication Number Publication Date
KR890001571A true KR890001571A (ko) 1989-03-27
KR920004097B1 KR920004097B1 (ko) 1992-05-25

Family

ID=22118217

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880008864A KR920004097B1 (ko) 1987-07-16 1988-07-15 독소루비신 히드로클로라이드 수용액

Country Status (11)

Country Link
EP (1) EP0299527B1 (ko)
JP (1) JPH0655668B2 (ko)
KR (1) KR920004097B1 (ko)
AT (1) ATE74759T1 (ko)
AU (1) AU612379B2 (ko)
DE (1) DE3870064D1 (ko)
DK (1) DK396288A (ko)
ES (1) ES2033379T3 (ko)
FI (1) FI883338A (ko)
GR (1) GR3004383T3 (ko)
PT (1) PT88016B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100327400B1 (ko) * 1998-04-07 2002-05-09 구자홍 음극선관용편향요크

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI895733A0 (fi) * 1988-12-05 1989-11-30 Bristol Myers Squibb Co Vattenloesningar av doxorubicin.
JP3236608B2 (ja) * 1990-10-04 2001-12-10 日本化薬株式会社 ブレオマイシン類の安定な水溶液
FR2690340B1 (fr) * 1992-04-24 1995-02-24 Scr Newmed Nouveau procédé de stabilisation des préparations pharmaceutiques liquides et les compositions pharmaceutiques ainsi stabilisées en résultant.
RU2162699C1 (ru) * 2000-02-14 2001-02-10 Закрытое Акционерное Общество "Нита-Фарм" Водно-дисперсная лекарственная форма ивермектина для лечения экто- и эндопаразитозов
JP2002037737A (ja) * 2001-08-02 2002-02-06 Nippon Kayaku Co Ltd ブレオマイシン類の安定な水溶液
AU2006213440A1 (en) * 2005-02-11 2006-08-17 Dabur Pharma Limited Stabilized anthracycline glycoside pharmaceutical compositions
KR20070088447A (ko) * 2005-05-11 2007-08-29 시코르, 인크. 안정한 동결건조된 안트라사이클린 글리코시드
WO2007075092A1 (en) * 2005-12-29 2007-07-05 Instytut Biochemii I Biofizyki New derivatives of epirubicin, their medicinal application and pharmaceuticals acceptable forms of drugs
CN111050750A (zh) 2017-08-24 2020-04-21 诺沃挪第克公司 Glp-1组合物及其用途
MX2022009523A (es) 2020-02-18 2022-09-09 Novo Nordisk As Formulaciones farmaceuticas.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA795492B (en) * 1978-10-20 1981-05-27 Lilly Co Eli Stable erythromycin solution
GB8519452D0 (en) * 1985-08-02 1985-09-11 Erba Farmitalia Injectable solutions
DE3537761A1 (de) * 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100327400B1 (ko) * 1998-04-07 2002-05-09 구자홍 음극선관용편향요크

Also Published As

Publication number Publication date
DK396288A (da) 1989-01-17
EP0299527A1 (en) 1989-01-18
ES2033379T3 (es) 1993-03-16
PT88016A (pt) 1989-06-30
ATE74759T1 (de) 1992-05-15
PT88016B (pt) 1995-03-01
DK396288D0 (da) 1988-07-15
JPH0655668B2 (ja) 1994-07-27
AU612379B2 (en) 1991-07-11
KR920004097B1 (ko) 1992-05-25
FI883338A0 (fi) 1988-07-13
JPH01117894A (ja) 1989-05-10
AU1905388A (en) 1989-01-19
DE3870064D1 (de) 1992-05-21
FI883338A (fi) 1989-01-17
EP0299527B1 (en) 1992-04-15
GR3004383T3 (ko) 1993-03-31

Similar Documents

Publication Publication Date Title
KR870005637A (ko) 약물 데포
CO4700482A1 (es) Formulaciones de un analogo monomero de insulina
BR0211794A (pt) Composição farmacêutica e método para mascarar o sabor de pelo menos um composto farmaceuticamente ativo de sabor desagradável
KR890001571A (ko) 독소루비신 히드로클로라이드 수용액
KR970706017A (ko) 안정한 알파 인터페론 수용액 제형(Stable, aqueous alfainterfer on solution for mulations)
ES2035821T3 (es) Sistema de administracion enterica dirigida.
KR970025615A (ko) 암 전이 억제제
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
KR880007060A (ko) 제약 조성물
US3230143A (en) Antihypertensive injection methods using acid addition salts of alkyl esters of alpha-methyl-3, 4-dihy-droxyphenylalanine
FI75991B (fi) Foerfarande foer framstaellning av stabil isotonisk vaetskekomposition, vilken kan anvaendas som oegonmedicinpreparat.
PE20030545A1 (es) Formulaciones de jarabe de ribavirina
KR890001570A (ko) 독소루비신 히드로클로라이드 비수성 용액
US3526698A (en) Stabilization of levo-3-(3,4-dihydroxyphenyl)-2-methylalanine with sodium bisulfite and sorbitol
KR950005325A (ko) 제약 조성물
US6143795A (en) Stable mitoxantrone solutions
ATE223700T1 (de) Ramoplaninhaltige neue injizierbare arzneizubereitungen
KR950016756A (ko) 피로회복제 조성물
FI895733A0 (fi) Vattenloesningar av doxorubicin.
KR927003055A (ko) 케토티펜 외용제제
KR960033455A (ko) 항암조성물
DE68905577D1 (de) Doxorubicin-loesungen.

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee